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Background
Diamond Blackfan anemia (DBA), characterized by impaired red cell production, is a rare 
condition that is usually symptomatic in early infancy. The purpose of this study was to 
assess nationwide experiences of DBA encountered over a period of 20 years. 
Methods
The medical records of 56 patients diagnosed with DBA were retrospectively reviewed 
from November 1984 to July 2010. Fifteen institutions, including 13 university hospitals, 
participated in this study. 
Results
The male-to-female ratio of patients with DBA was 1.67:1. The median age of diagnosis 
was 4 months, and 74.1% were diagnosed before 1 year of age. From 2000 to 2009, annual 
incidence was 6.6 cases per million. Excluding growth retardation, 38.2% showed con-
genital defects: thumb deformities, ptosis, coarctation of aorta, ventricular septal defect, 
strabismus, etc. The mean hemoglobin concentration was 5.1±1.9 g/dL, mean corpus-
cular volume was 93.4±11.6 fL, and mean number of reticulocytes was 19,700/mm3. 
The mean cellularity of bone marrow was 75%, with myeloid:erythroid ratio of 20.4:1. 
After remission, 48.9% of patients did not need further steroids. Five patients with DBA 
who received hematopoietic transplantation have survived. Cancer developed in 2 cases 
(3.6%). 
Conclusion
The incidence of DBA is similar to data already published, but our study had a male 
predilection. Although all patients responded to initial treatment with steroids, about half 
needed further steroids after remission. It is necessary to collect further data, including 
information regarding management pathways, from nationwide DBA registries, along 
with data on molecular analyses.
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INTRODUCTION
Diamond Blackfan anemia (DBA; OMIM 205900), charac-
terized by impaired red cell production, is a rare condition 
that is usually symptomatic in early infancy. DBA was first 
recognized as a distinct clinical entity in 1938 [1]. The diag-
nostic criteria for DBA that were developed in 1976 have 
remained the accepted standard [2] and include anemia, usu-
ally presenting prior to the first birthday, with near normal 
neutrophil and/or platelet counts, reticulocytopenia, macro-
cytosis, and normal marrow cellularity with a paucity of 
red cell precursors. These criteria comprise “classical” DBA. 
The disorder results from a cellular defect, in which erythroid 
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Table 1. Clinical and laboratory findings at diagnosis in 56 patients
with Diamond Blackfan anemia.
Clinical characteristics  N   %
Gender
Male       35     62.5
Female       21     37.5
Family history
Yes         3       5.4
Age at diagnosis
＜6 mo       31     57.4
＜12 mo         9     16.7
＞12 mo       14     25.9 
Unknown         2       3.6
Laboratory findings Mean±SD   Range
Red blood cells, 106/mm3    1.88±0.93 0.49-4.7
Hemoglobin, g/dL       5.1±2.1   1.5-9.8
MCV, fL    93.4±11.6 74.0-116.6
MCH, pg    31.1±4.0 23.4-40.3
HbF, %       7.7±11.3      0-49.9
Adenosine deaminase, U/L    21.1±13.7   3.5-48.5
Bone marrow 
Cellularity    75.3±20.4    30-100
M:E ratio    20.4±21.3   1.9-100
Abbreviations: MCV, mean corpuscular volume; MCH, mean 
corpuscular hemoglobin; HbF, fetal hemoglobin; M:E ratio, 
myeloid:erythroid ratio.
Table 2. Congenital anomalies observed in 56 patients with 
Diamond Blackfan anemia.
 N
Craniofacial
Cleft palate 2
Ophthalmologic
Ptosis 5
Strabismus 3
Entropion 1
Neck
Webbed neck 1
Klippel-Feil syndrome 1
Short neck 1
Thumbs
Thumb deformities 8
Cardiac
VSD 4
ASD 1
Complex cardiac anomalies 1
Coarctation of aorta 5
Mitral valve prolapse 2
Other musculoskeletal
Growth retardation 4
Failure to thrive 1
Neuromotor
Hearing loss 1
Total 　 41
Abbreviations: VSD, ventricular septal defect; ASD, atrial septal 
defect.
progenitors and precursors are highly sensitive to death by 
apoptosis, leading to erythropoietic failure [3-5].
DBA came into the scientific spotlight after the identi-
fication of RPS19, the gene encoding ribosomal protein S19 
[6]. Since then, many genes that encode large (RPL) and 
small (RPS) ribosomal subunit proteins have been found 
to be mutated in DBA patients, such as RPL5, RPL11, 
RPL35A, RPS7, RPS10, RPS17, RPS24, and RPS26 [7-10]. 
Although the first case of DBA was reported in 1974 in 
Korea [11], there is relatively limited data regarding DBA. 
Recently, direct sequencing analysis of the RPS19 gene was 
performed with both cDNA and genomic DNA extracted 
from peripheral blood, and a c.3G＞A point mutation in 
exon 2 resulting in a p.Met1Ile substitution was identified 
in a 3-month-old infant [12]. 
In this report, we reviewed the clinical characteristics 
of 56 patients with DBA from a 20-year birth cohort in 
Korea to provide further information for molecular analyses. 
MATERIALS AND METHODS
The medical records of 56 patients diagnosed with DBA 
were retrospectively reviewed from November 1984 to July 
2010. Thirteen university hospitals participated in this study. 
Diagnostic and supporting criteria for the diagnosis of DBA 
are as follows: normochromic, often macrocytic anemia, re-
ticulocytopenia, and a low number or lack of erythroid pre-
cursors in the bone marrow. In only two patients, diagnoses 
were confirmed by mutation analyses [12]. Clinical in-
formation, including records on birth history, age of onset 
and diagnosis, family history, height and weight, malforma-
tions, hematologic data, response to therapeutic procedures, 
and prognosis, was obtained via a standardized questionnaire. 
Remission was defined as a stable, physiologically acceptable 
hemoglobin (Hb) level maintained for at least 6 months 
independent of corticosteroids, transfusions, or other the-
rapy.
Means and standard deviations were used in the statistical 
analysis. Statistical significance was defined as P＜0.05. 
RESULTS
The male to female ratio of patients was 1.67:1 (35 males, 
21 females) as shown in Table 1. Among the patients diag-
nosed after 2000, the male-to-female ratio was 1.62:1 (21 
males, 13 females). Only 3 cases (5.4%) revealed a family 
history. However, the genetic study was not done in the 
patients and family members.
The median age of diagnosis was 4 months, and the range 
was birth to 52 months of age. The proportion of patients 
diagnosed before 1 year was 74.1% (40/54), excluding 2 pa-
tients without age documents at diagnosis. From 2000 to 
2009, 33 cases with DBA were registered, yielding an in-
cidence of 6.6 cases per million, based on the Korean annual 
birth rate of 500,000. The mean Hb concentration was 5.0±1.8 
g/dL (range, 1.5-9.8 g/dL), and the median was 5.2 g/dL. 
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Table 3. Side effects of steroid treatment in patients with Diamond
Blackfan anemia.
 N
Cosmetic
Hirsutism 3
Moon face 6
Weight gain 1
Behavioral
Depression 1
Endocrine
Impaired glucose tolerance 3
Diabetes mellitus 2
Menstrual irregularities 1
Growth
Impaired growth velocity 13
Immunosuppression
Candida 1
Total 31
The mean value of the mean corpuscular volume (MCV) 
was 93.4±11.6 fL and mean fetal hemoglobin (HbF) level 
was 7.7±11.3%. The mean number of corrected reticulocytes 
was markedly lower than normal (19,700/mm3). The mean 
adenosine deaminase level was higher than normal, at 
21.3±14.4 U/L. The mean cellularity of the bone marrow 
was 75%, and the myeloid:erythroid (M:E) ratio was 20.4:1 
(range, 1.9:1 to 100:1). Among 28 patients with chromosomal 
analysis data, 26 showed a normal pattern in routine cytoge-
netic analysis. Direct sequencing analysis of the RPS19 gene 
was performed in 2 patients, who had the substitutions 
c.357-2A＞G (RPS19) and c.3G＞A (Met1Ile), respectively. 
Excluding growth retardation, 21 cases (38.2%) showed 
congenital defects: thumb deformities (8 cases), ptosis (5), 
coarctation of aorta (5), ventricular septal defect (4), stra-
bismus (3), cleft palate (2), and mitral valve prolapse (2). 
More than one anomaly was found in 21.2% of individuals 
(Table 2).
Thirty-two patients had a history of transfusion after the 
initial correction of Hb at diagnosis. All patients initially 
received corticosteroids, and 83.9% (47/56) responded with 
an increase in Hb. In 48.9% (23/47) of patients, steroids 
were eventually stopped with continued maintenance of ad-
equate hemoglobin levels. The mean duration of steroid use 
was 7 years (maximum, 22 yrs). Complications due to steroid 
therapy were reported in 31 cases, including growth re-
tardation (13), moon face (6), hirsutism (3), impaired glucose 
tolerance (3), and diabetes mellitus (2) (Table 3). Among 
the 28 patients who received steroids, 9 patients were on 
a well-controlled regimen, with a daily dose of 5 mg or 
less.
Iron chelation therapy was attempted in 6 patients with 
high serum ferritin levels (usually more than 1,000 ng/mL): 
deferoxamine (Desferal) intravenously in 3 cases, and more 
recently, deferasirox (Exjade) in 4 cases.
Five patients underwent hematopoietic stem cell trans-
plantation (HSCT) at 81±46 months (range, 22-150 months). 
Transplantation sources were bone marrow from related do-
nors (3 patients), bone marrow from unrelated donors (1 
patient), and peripheral blood from unrelated donor (1 pa-
tient). Four recipients underwent conditioning without 
irradiation. Graft-versus-host disease prophylaxis included 
methotrexate (3 patients) and antithymocyte globulin (3 pa-
tients). All 5 patients have survived. Only one patient was 
lost to follow-up at the well-being state.
In the median follow-up of 8 years, there were 2 cases 
(3.6%) of malignancy: diffuse large cell lymphoma after 8 
months and osteosarcoma after 13 years of DBA. The latter 
died due to lung metastasis and pulmonary hypertension.
DISCUSSION
DBA is characterized by macrocytic anemia, reticulocy-
topenia, and normal bone marrow cellularity with a paucity 
of erythroid precursors. DBA is caused by a defect in which 
erythroid progenitors and precursors are highly sensitive 
to death by apoptosis, leading to erythropoietic failure [4, 
5, 13].
As in this study, routine cytogenetic analysis of patients 
with DBA is normal. However, a balanced reciprocal trans-
location t(X;19) was discovered in a DBA patient [6], reveal-
ing the first DBA gene (DBA1) that encodes a ribosomal 
protein S19 (RPS19) that is essential for the maturation of 
the 40S ribosomal subunit [14]. The identification of sub-
sequent DBA genes has established DBA as a ribosomal dis-
order, because the affected gene encodes ribosomal proteins 
[8]. RPS19 protein haploinsufficiency is not sufficient to 
produce normal function. Recently, de novo mutations have 
been identified in ribosomal proteins RPS24 [8], RPS17, 
RPL5, RPL11, and RPL35a. To date, approximately 50% of 
DBA patients have a single mutation in a gene encoding 
a ribosomal protein. These findings implicate DBA as a dis-
order of ribosome biogenesis and/or function.
The diagnostic criteria for “classical” DBA, presented in 
1976 [2], include the followings: anemia, usually presenting 
prior to the first birthday, with near normal, but variable, 
neutrophil and/or platelet counts; reticulocytopenia; macro-
cytosis; and normal marrow cellularity with a paucity of 
red cell precursors. “Non-classical” DBA is characterized by 
presentation at an age ＞1 year, with congenital anomalies, 
no anemia, a mild hematological phenotype (macrocytosis 
only), or the presence of a mutation shared by affected family 
members.
Although all immediate family members should be eval-
uated with a thorough relevant history, and a complete blood 
count, including red cell indices, erythrocyte adenosine de-
aminase (eADA) activity, and HbF, these were not com-
pletely performed in our study. This may be the reason 
why only 3 cases in our study revealed a family history. 
Generally, 40-45% of DBA cases are familial with autosomal 
dominant inheritance [15], and the remainder is sporadic 
or familial with seemingly different patterns of inheritance. 
In a study of 80 DBA patients in the United Kingdom 
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[16], 35% of classical DBA patients were found to have one 
or more unequivocal congenital anomalies, not including 
growth retardation. A similar proportion has been described 
in the French, Italian, and North American registries (40%, 
46%, and 47%, respectively) [3, 17, 18]. More than one 
anomaly was found in up to 25% of individuals. In this 
study, 21 cases (38.2%) showed congenital defects, with more 
than one anomaly in 21.2%. Renal anomalies have not been 
seen. However, in the North American Diamond Blackfan 
Anemia Registry (DBAR), where the majority of patients 
undergo formal genitourinary and cardiac imaging, the prev-
alence is 19%.
The incidence of DBA is estimated to be between 1 in 
100,000 and 1 in 200,000 without ethnic predilection, and 
both sexes are reported to be equally affected [3, 16-19]. 
In our study, the prevalence of DBA was similar to these 
statistics (6.6 cases per million), but with a male predilection 
(M:F=1.67:1).
The reported proportion of cancer is 4% (29/700) in pa-
tients with DBA, which is higher than the expected 0.5% 
for a cohort less than 30 years of age [20, 21]. The median 
age for cancer in these reports was 15 years, much younger 
than the median of 68 years in the general population [22]. 
The crude frequency reported from Boston Children's 
Hospital was 6.6% [23], the French series 3.8% [18], and 
the DBAR 1.9% (8/420) [3]. In this study, 2 cases (3.6%) 
with DBA developed cancer: osteogenic sarcoma and diffuse 
large cell lymphoma, respectively.
Corticosteroids remain the mainstay of DBA treatment. 
The therapeutic mechanism of corticosteroids in DBA may 
involve increased sensitivity to erythropoietin (Epo) [4, 24]. 
Remission occurred in 48.9%. The initial recommended start-
ing dose was 2 mg/kg prednisone or the glucocorticoid 
equivalent. Most patients are controlled with the recom-
mended maximum maintenance dose (≤1 mg/kg every other 
day or ≤0.5 mg/kg daily). Seventy percent of those who 
achieved remission did so within the first decade of life.
Complications due to steroid therapy were noted in 20% 
of patients on long-term steroid therapy [18], and 22% of 
those in the DBAR [3]. In our study, growth retardation 
was most common, followed by moon face, hirsutism, im-
paired glucose tolerance, and diabetes mellitus. Growth hor-
mone therapy has been used successfully to increase growth 
velocity [25]. In our study, 1 patient who had been diagnosed 
with growth hormone deficiency showed good response to 
recombinant growth hormone therapy for 1.5 yrs (height 
increased from less than the 3rd percentile to the 10th per-
centile), without bone age advancement.
Addition of iron-chelating therapy is recommended in 
transfusion-dependent patients, because prolonged iron ac-
quisition from transfusion can cause a potentially fatal iron 
overload in the liver, heart, or pancreas. Iron chelation was 
initiated when a ferritin level was 1,000 ng/mL or more 
instead of the hepatic iron concentration reaching 6-7 mg/g 
dry weight. Chelation by subcutaneous deferoxamine 
(Desferal, Novartis) was switched in 2007 to oral deferasirox 
(ICL670, Exjade, Novartis), which is now approved in Korea 
as the first-line therapy for transfusional iron overload [26]. 
Hematopoietic stem cell transplantation (HSCT) is the 
curative treatment for DBA [3, 18, 27, 28]. According to 
the DBAR [3], where the major indication for HSCT was 
transfusion dependence, the bone marrow was the most com-
mon source of stem cells. The survival rate for allogeneic 
sibling versus alternative donor transplant was 72.7% vs. 
17.1% at ＞5 years following SCT. The survival for patients 
＜10 years of age who underwent transplantation from hu-
man leukocyte antigen (HLA)-matched allogeneic siblings 
was 92.3% [19]. More recently, successful related umbilical 
cord blood and unrelated donor transplants have been re-
ported to the DBAR, but it is too early for a meaningful 
analysis of the data.
In conclusion, the incidence of DBA is similar to data 
already published, but there was a male predilection in our 
study. Although all patients responded to initial treatment 
with steroids, about half needed further steroids after 
remission. It is necessary to collect further data, including 
information on management pathways, from nationwide 
DBA registries, in addition to molecular analyses. Since DBA 
patients need lifetime care, they should be managed by a 
multidisciplinary team involving pediatric and adult hema-
tologists, internists, and subspecialists.
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